Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry. This journal is © The Royal Society of Chemistry 2022

Supporting Information

Palladium-catalysed C_{sp3}-H functionalization of unactivated 8- aminoquinoline amides in Deep Eutectic Solvents

Xavier Marset^[a]

^[a] Instituto de Síntesis Orgánica (ISO) and Departamento de Química Orgánica. Facultad de Ciencias. Universidad de Alicante. Apdo. 99, E-03080-Alicante, Spain.

Corresponding author: <u>xavier.marset@ua.es</u>

Table of contents

Materials and Methods	2
General	2
Optimisation studies	3
General procedures	4
Deep Eutectic Solvents preparation	4
Synthesis of starting materials	4
General procedure A4 General procedure B5 Arylation/Alkynilation reactions	5
General procedure C5 General Procedure for Recycling Experiments:5 Characterisation data	6
Competitive experiment	11
NMR Spectra	13
References	39

Materials and Methods

General

Melting points were obtained with a *Reichert Thermovar* apparatus. NMR spectra were recorded on a *Bruker AC- 300* (300 MHz for ¹H and 75 MHz for ¹³C) using CDCl₃ as a solvent (unless otherwise stated). ¹H and ¹³C chemical shifts are given in δ (parts per million) and coupling constants (*J*) in Hertz. FT-IR spectra were obtained on *a JASCO 4100LE (Pike Miracle ATR)* spectrophotometer. Mass spectra (EI) were obtained at 70 eV on a *Agilent Technologies* GC/MS-8890N, giving fragment ions in *m/z* with relative intensities (%) in parentheses. The mass spectrometry analyses of high resolution (HRMS) were performed in the Mass Spectrometry Unit of the Technical Services Research at the University of Alicante with a spectrometer *Agilent 7200* using Electronic Impact for ionization and Q-TOF for mass measurement. Thin layer chromatography (TLC) was carried out on *Schleicher&Schuell* F1400/LS 254 plates coated with a 0.2 mm layer of silica gel; detection by UV₂₅₄ light. Column chromatography was performed using silica gel 60 of 40-63 mesh. All reagents were commercially available (*Acros, Aldrich, Fluorochem*) and were used as received.

Optimisation studies



4-iodoanisole(3.0 equiv.) Pd(OAc)₂ (10 mol%) Base (equiv.) 2-pyridone (40 mol%) ► DES (0.2 M) T (°C), 16 h



Entry	Solvent	Base (equiv.)	Т (°С)	Conversion 3a (%) ^a
1	ChCl:Glycerol (1:2)	K ₂ CO ₂ (1.5)	110	41
2	ChCl:Glycerol (1:2)	K ₂ CO ₂ (1.5)	110	0 ^b
3	AcChCl:Acetamide (1:2)	K ₂ CO ₂ (1.5)	110	63
4	ChCl:Acetamide (1:2)	K ₂ CO ₂ (1.5)	110	74
5	Ph₃PMeBr:Glycerol (1:2)	K ₂ CO ₂ (1.5)	110	0
6	ChCl:Resorcinol (1:1)	K ₂ CO ₂ (1.5)	110	3
7	$ChCl:(CH_2OH)_2$ (1:2)	K ₂ CO ₂ (1.5)	110	23
8	Betaine:Glycerol (1:2)	K ₂ CO ₂ (1.5)	110	47
9	ChCl:Urea (1:2)	K ₂ CO ₂ (1.5)	110	12
10	Decanoic acid:Menthol (1:2)	K ₂ CO ₂ (1.5)	110	0
11	AcChCl:Glycerol (1:2)	K ₂ CO ₂ (1.5)	110	32
12	Betaine:Lactic Acid (1:2)	K ₂ CO ₂ (1.5)	110	13
13	L-Carnitine:Urea (1:2)	K ₂ CO ₂ (1.5)	110	28
14	ChCl:Acetamide (1:2)	NaOAc (1.5)	110	85
15	ChCl:Acetamide (1:2)	Na₂CO₃ (1.5)	110	87
16	ChCl:Acetamide (1:2)	K ₃ PO ₄ (1.5)	110	70
17	ChCl:Acetamide (1:2)	^t BuOK (1.5)	110	3
18	ChCl:Acetamide (1:2)	Na₃PO₄ (1.5)	110	84
19	ChCl:Acetamide (1:2)	Ag ₂ CO ₃ (1.5)	110	32
20	ChCl:Acetamide (1:2)	NaOH (1.5)	110	22
21	ChCl:Acetamide (1:2)	NaHCO₃ (1.5)	110	93 (88) ^c
23	ChCl:Acetamide (1:2)	NaHCO₃ (1.5)	110	74 ^d
24	ChCl:Acetamide (1:2)	NaHCO₃ (1.5)	110	85 ^e
26	ChCl:Acetamide (1:2)	NaHCO₃ (1.5)	110	93 ^f
27	ChCl:Acetamide (1:2)	NaHCO₃ (2.0)	110	62
28	ChCl:Acetamide (1:2)	NaHCO₃ (3.0)	110	29
29	ChCl:Acetamide (1:2)	NaHCO₃ (1.5)	100	85
30	ChCl:Acetamide (1:2)	NaHCO ₃ (1.5)	90	64
31	HFIP + 0.5 equiv. Betaine	NaHCO₃ (1.5)	110	34
32	K ₂ CO ₃ :Ethyleneglycol (1:10)	-	110	58
33	ChCl:Acetamide (1:2)	NaHCO₃ (1.5)	110	43 ^g
34	ChCl:Acetamide (1:2)	NaHCO₃ (1.5)	110	85 ^h
35	Betaine:HFIP (1:2)	NaHCO₃ (1.5)	110	100 (97)°
36	HFIP	NaHCO₃ (1.5)	110	55
37	Neat conditions	NaHCO₃ (1.5)	110	10
38	H ₂ O	NaHCO₃ (1.5)	110	45
39	<i>t</i> BuOH	NaHCO₃ (1.5)	110	5
40	PhMe	NaHCO ₂ (1.5)	110	15

^a Conversion determined by GC-MS. ^b Reaction performed with substrate **2ab**. ^cIsolated yield. ^d Reaction performed without ligand. ^e Reaction performed with 20 mol% of ligand. ^f Reaction performed with PdCl₂ instead of Pd(OAc)₂. ^g Reaction performed with 1.0 equiv of 4-iodoanisole. ^h Reaction performed with 2.0 equiv. of 4-iodoanisole.

Chart S1. Inefficient substrates.



General procedures

Deep Eutectic Solvents preparation

DESs were prepared by mixing the corresponding components in the appropriate molar ratio and heating the mixture at 80 °C under Ar atmosphere until a clear solution was obtained. Since some of the components of DESs are very hygroscopic, they were always stored under Ar atmosphere, although the reactions employing DESs as solvents were carried out in opened to air reaction vessels.

Synthesis of starting materials

General procedure A:



For commercially available anhydrides or acid chlorides a literature procedure was adapted:^[1] 8aminoquinoline (1.0 equiv.) and Et_3N (1.05 equiv.) were dissolved in DCM. The solution was cooled to 0 °C the corresponding acid anhydride or acid chloride (1.05 equiv.) was slowly added. The mixture was allowed to warm to room temperature and stirred overnight. The reaction was transferred to a separatory funnel and washed with water, NaHCO₃ (sat. aq.) and brine. The organic phase was dried over MgSO₄, filtered, and concentrated under reduced pressure. Products were purified by column chromatography using mixtures of hexane and ethyl acetate as eluent.

General procedure B:



For non-commercially available acid chlorides or anhydrides: The corresponding acid (1.0 equiv.) was placed in a Schlenk flask, and the system was evacuated and backfilled with Ar (x3). Dry DCM was added (concentration of acid 0.25 M) followed by dry DMF (20 μ L/mmol of acid). The mixture was cooled to 0 °C and oxalyl chloride (1.5 equiv.) was slowly added. The reaction was allowed to warm to room temperature and stirred for 45 min. Then, volatiles were removed under reduced pressure. The resulting residue was redissolved in dry DCM under Ar atmosphere, cooled to 0 °C and 8-aminoquinoline (1.2 equiv.) was added. After stirring for 10 min, Et₃N (2.0 equiv.) was added, and the mixture was allowed to reach room temperature and was stirred overnight. The reaction was quenched by addition of saturated NaHCO₃ aqueous solution and extracted with DCM (x3). The combined organic phase was dried over MgSO₄, filtered, and concentrated under reduced pressure. Products were purified by column chromatography using mixtures of hexane and ethyl acetate as eluent.

Arylation/Alkynylation reactions

<u>General procedure C</u>: $Pd(OAc)_2$ (4.5 mg, 0.02 mmol), 2-pyridone (7.6 mg, 0.08 mmol), NaHCO₃ (25 mg, 0.30 mmol), and the corresponding amide (0.20 mmol) and aryl halide (0.60 mmol) were charged in a reaction vessel. Next, 1 mL of DES [ChCl:Acetamide (1:2) or Betaine:HFIP (1:2)] previously heated to 80 °C was added and the reaction was heated to 110 °C under air atmosphere and magnetic stirring for 12 h (in ChCl:Acetamide/1:2) or 2.5 h (in betaine:HFIP/1:2). Once the reaction was finished, it was quenched by addition of water (3.0 mL) and extracted with EtOAc (3x5 mL). The combined organic extracts were dried over MgSO₄, filtered, and concentrated in vacuo. Arylated products were purified by column chromatography or preparative TLC using mixtures of hexanes and EtOAc.

<u>General Procedure for Recycling Experiments</u>: reaction was performed according to general procedure C. Once the reaction was completed, the reaction mixture was cooled to room temperature, and 2-MeTHF ($3 \times 1 \text{ mL}$) was added to the reaction vessel for reactions performed in ChCl:acetamide (1:2). In the case of using Betaine:HFIP (1:2) as reaction media, PhMe was employed as extraction solvent. The biphasic mixture was stirred for 5 min and the upper phase, containing unreacted organic reagents and products, was separated by decantation and



analysed by ¹H NMR using 1,2,4,5-tetramethylbenzene as internal standard. The eutectic mixture was dried under vacuum and was charged again with fresh amide, aryl iodide and sodium bicarbonate, repeating the process.

Characterisation data



N-(quinolin-8-yl)decanamide (2aa):^[2] Prepared from general procedure B (2.44 g, 82% yield). Pale yellow solid. m.p. = 48-50 °C. R_f = 0.58 (hexane:EtOAc = 4:1). ¹H NMR (CDCl₃, 400 MHz): δ 9.85 (s, 1H), 8.83 – 8.75 (m, 2H), 8.17 (dd, *J* = 8.3, 1.7 Hz, 1H), 7.58 – 7.39 (m, 3H), 2.56 (t, *J* = 7.5 Hz, 2H), 1.87 – 1.75 (m, 2H),

1.48 – 1.20 (m, 12H), 0.91 – 0.81 (m, 3H). ¹³C NMR (CDCl₃, 101 MHz): δ 172.1, 147.8, 138.0, 136.8, 134.4, 128.0, 127.6, 121.5, 121.4, 116.8, 38.3, 31.9, 29.5, 29.4, 29.3 (2C), 25.7, 22.7, 14.1. MS m/z 298 (M⁺, 16%), 208 (12), 207 (53), 186 (100), 171 (64). IR (neat, cm⁻¹) $\tilde{\nu}$: 3340, 2923, 2850, 1681, 1523, 1477, 1165, 687.



N-(pyridin-2-ylmethyl)decanamide (2ab):^[3] Compound synthetised following general procedure B, substituting 8aminoquinoline by 2-picolylamine (2.23 g, 85% yield). Yellowish solid. m.p. = 41-43 °C. $R_{\rm f}$ = 0.45 (EtOAc). ¹H NMR

(CDCl₃, 400 MHz): δ 8.50 (ddd, *J* = 4.9, 1.8, 1.1 Hz, 1H), 7.65 (td, *J* = 7.7, 1.8 Hz, 1H), 7.27 (dt, *J* = 7.7, 1.1 Hz, 1H), 7.19 (ddd, *J* = 7.7, 4.9, 1.1 Hz, 1H), 6.89 (s, 1H), 4.53 (d, *J* = 5.1 Hz, 2H), 2.27 – 2.22 (m, 2H), 1.63 (td, *J* = 10.1, 4.6 Hz, 2H), 1.31 – 1.20 (m, 10H), 0.84 (t, *J* = 6.9 Hz, 3H). ¹³C NMR (CDCl₃, 101 MHz): δ 173.5, 156.87, 148.8, 137.2, 122.5, 122.5, 44.4, 36.8, 31.9, 29.5, 29.4, 29.4, 29.3, 3.8, 22.7, 14.2. MS m/z 262 (M⁺, 28%), 205 (11), 177 (11), 163 (35), 151 (15), 150 (100). IR (neat, cm⁻¹) $\tilde{\nu}$: 3301, 2919, 2854, 1643, 1550, 1427, 717.



N-(quinolin-8-yl)octanamide (2b):^[4] Obtained following general procedure A (2.48 g, 92% yield). Brown oil. R_f = 0.55 (hexane:EtOAc = 4:1). ¹H NMR (CDCl₃, 300 MHz): δ 9.80 (s, 1H), 8.83 – 8.71 (m, 2H), 8.11 (dd, J = 8.3, 1.7 Hz, 1H), 7.55 – 7.35 (m, 3H), 2.54 (t, J = 7.7 Hz, 2H), 1.80 (tt, J = 8.4, 6.2 Hz, 2H), 1.47 – 1.21 (m, 8H), 0.92 – 0.81 (t, J = 6.8 Hz, 3H). ¹³C NMR (CDCl₃, 75 MHz): δ

172.0, 148.0, 136.5, 134.6, 128.0, 127.5, 121.6, 121.4, 116.6, 38.3, 31.8, 29.3, 29.1, 25.7, 22.7, 14.1. MS m/z 270 (M⁺, 24%), 207 (42), 199 (19), 187 (14), 186 (100), 171 (79). IR (neat, cm⁻¹) $\tilde{\nu}$: 3355, 2927, 2858, 1685, 1523, 1481, 1326, .729.



N-(quinolin-8-yl)butyramide (2c):^[1] Obtained following general procedure A (1.93 g, 90% yield). Brown oil. R_f = 0.45 (hexane:EtOAc = 4:1). ¹H NMR (CDCl₃, 300 MHz): δ 9.82 (s, 1H), 8.90 – 8.70 (m, 2H), 8.15 (dd, *J* = 8.3, 1.7 Hz, 1H), 7.58 – 7.35 (m, 3H), 2.54 (dd, *J* = 7.9, 7.1 Hz, 2H), 1.94 – 1.77 (m, 2H), 1.05 (t, *J* = 7.4 Hz, 3H). ¹³C NMR (CDCl₃, 75 MHz): δ 171.9, 148.1, 138.3, 136.6, 134.6, 128.1,

127.6, 121.6, 121.5, 116.7, 40.2, 19.2, 13.9. MS m/z 214 (M⁺, 25%), 171 (42), 145 (12), 144 (100). IR (neat, cm⁻¹) $\tilde{\nu}$: 3353, 2962, 1681, 1523, 1481, 1322, 1172, 790.



N-(quinolin-8-yl)cyclohexanecarboxamide (2d):^[1] Obtained following general procedure A (1.65 g, 65% yield). Pale brown solid. m.p. = 60-62 °C. R_f = 0.56 (hexane:EtOAc = 4:1). ¹H NMR (CDCl₃, 400 MHz): δ 9.94 (s, 1H), 8.82 (dt, *J* = 5.3, 1.5 Hz, 2H), 8.22-8.12 (m, 1H), 7.59 – 7.43 (m, 3H), 2.57 – 2.46 (m, 1H), 2.13 – 2.06 (m, 2H), 1.88 (dt, *J* = 12.7, 3.3 Hz, 2H), 1.75 (dtd, *J* = 10.9, 3.1, 1.6 Hz, 1H),

1.70 – 1.60 (m, 2H), 1.46 – 1.28 (m, 3H). ¹³C NMR (CDCl₃, 101 MHz): δ 175.0, 147.9, 138.2, 136.7, 134.5, 128.0, 127.6, 121.5, 121.3, 116.8, 46.9, 29.8, 25.8, 25.6. MS m/z 254 (M⁺, 37%), 208 (14), 172 (12), 171 (100). IR (neat, cm⁻¹) $\tilde{\nu}$: 3340, 2923, 2850, 1685, 1519, 1477, 1322, 1160.



N-(quinolin-8-yl)pivalamide (2f):^[5] Obtained following general procedure A (2.14 g, 94% yield). Yellow oil. R_f = 0.61 (hexane:EtOAc = 4:1). ¹H NMR (CDCl₃, 400 MHz): δ 10.27 (s, 1H), 8.90 – 8.75 (m, 2H), 8.15 (dd, *J* = 8.3, 1.7 Hz, 1H), 7.58 – 7.41 (m, 3H), 1.43 (s, 9H). ¹³C NMR (CDCl₃, 101 MHz): δ 177.4, 148.3, 138.8, 136.6, 134.8, 128.1, 127.6, 121.6, 121.4, 116.5, 40.5, 27.9. MS m/z 228 (M⁺, 42%), 172 (36), 171

(100), 144 (45), 143 (14), 117 (13), 116 (15). IR (neat, cm⁻¹) $\tilde{\nu}$: 3363, 2962, 1677, 1523, 1481, 1326, 1157.



3-(4-methoxyphenyl)-*N*-(quinolin-8-yl)decanamide (3a): Obtained following general procedure C (78 mg, 97% yield). Pale brown solid. m.p. = 55-57 °C. R_f = 0.46 (hexane:EtOAc = 4:1). ¹H NMR (CDCl₃, 300 MHz): δ 9.68 (s, 1H), 8.80 – 8.69 (m, 2H), 8.12 (dd, *J* = 8.3, 1.7 Hz, 1H), 7.55 – 7.36 (m, 3H), 7.24 – 7.17 (m, 2H), 6.87 – 6.77 (m, 2H), 3.73 (s, 3H), 3.24 (dtd, *J* = 9.3, 7.3, 5.1 Hz, 1H), 2.90 – 2.73 (m, 2H), 1.71 (ddt, *J* = 23.0, 8.7, 4.8 Hz, 2H), 1.32 – 1.10 (m, 10H), 0.88 – 0.78 (t, *J* = 6.9 Hz, 3H). ¹³C NMR (CDCl₃, 75 MHz): δ

170.7, 158.1, 147.9, 136.5, 136.5, 134.5, 128.5, 128,0, 127.5, 121.6, 121.4, 116.65, 114,0, 55.2, 46.2, 42,0, 36.5, 31.9, 29.6, 29.3, 27.5, 22.7, 14.2. MS m/z 404 (M⁺, 4%), 282 (12), 253 (15), 209 (13), 208 (20), 207 (100) 191 (11). HRMS calcd. for $C_{26}H_{32}N_2O_2$ (M⁺): 404.2464, found: 404.2458. IR (neat, cm⁻¹) $\tilde{\nu}$: 3355, 2923, 2854, 1735, 1685, 1519, 1481, 1245, 1037.



N-(quinolin-8-yl)-3-(*p*-tolyl)decanamide (3b): Obtained following general procedure C (75 mg, 97% yield). Pale brown solid. m.p. = 40-42 °C. R_f = 0.48 (hexane:EtOAc = 4:1). ¹H NMR (CDCl₃, 300 MHz): δ 9.71 (s, 1H), 8.80 – 8.69 (m, 2H), 8.13 (dd, *J* = 8.2, 1.7 Hz, 1H), 7.57 – 7.36 (m, 3H), 7.19 (d, *J* = 8.2 Hz, 2H), 7.09 (d, *J* = 7.8 Hz, 2H), 3.26 (dtd, *J* = 9.4, 7.4, 5.1 Hz, 1H), 2.83 (dd, *J* = 7.4, 1.4 Hz, 2H), 2.28 (s, 3H), 1.81 – 1.62 (m, 2H), 1.32 – 1.12 (m, 10H), 0.84 (t, *J* = 6.7 Hz, 3H).¹³C NMR (CDCl₃, 101 MHz): δ 170.8, 147.8, 141.5, 138.0,

135.9, 134.4, 129.3, 128.1, 127.6, 127.5, 121.6, 121.5, 46.0, 42.4, 36.4, 31.9, 29.7, 29.3, 27.6, 22.7, 21.1, 14.2. MS m/z 388 (M⁺, 31%), 303 (23), 289 (11), 281 (37), 253(19), 208 (22), 207 (100), 191 (10), 186 (30), 171 (26), 159 (10). HRMS calcd. for $C_{26}H_{32}N_2O$ (M⁺): 388.2515, found: 388.2514. IR (neat, cm⁻¹) $\tilde{\nu}$: 3359, 2923, 2858, 1685, 1523, 1481, 1326, 821.



3-(3,4-dimethylphenyl)-*N***-(quinolin-8-yl)decanamide** (3c): Obtained following general procedure C (77 mg, 96% yield).Pale brown solid. m.p. = 47-48 °C. R_f = 0.48 (hexane:EtOAc = 4:1). ¹H NMR (CDCl₃, 400 MHz): δ 9.70 (s, 1H), 8.80 – 8.67 (m, 2H), 8.12 (dd, *J* = 8.3, 1.7 Hz, 1H), 7.55 – 7.38 (m, 3H), 7.09 – 7.00 (m, 3H), 3.24 (dtd, *J* = 9.5, 7.4, 5.1 Hz, 1H), 2.83 (dd, *J* = 7.3, 0.9 Hz, 2H), 2.21 (s, 3H), 2.18 (s, 3H), 1.84 – 1.64 (m, 2H), 1.32 – 1.15

(m, 10H), 0.85 (t, J = 6.9 Hz, 3H).¹³C NMR (CDCl₃, 101 MHz): δ 170.8, 147.9, 142.0, 136.6, 136.5, 134.5, 134.4, 129.8, 129.0, 127.5, 124.9, 121.5, 121.4, 116.7, 46.1, 42.3, 36.4, 31.9, 29.7, 29.3, 27.6, 22.7, 19.9, 19.4, 14.2. MS m/z 402 (M⁺, 100%), 318 (14), 317 (57), 304 (19), 303 (33), 281 (12), 253 (11), 209 (13), 208 (20), 207 (90), 186 (60), 172 (19), 171 (61), 169 (10), 159 (13). HRMS calcd. for C₂₇H₃₄N₂O₂ (M⁺): 402.2671, found: 402.2673. IR (neat, cm⁻¹) $\tilde{\nu}$: 3359, 2923, 2854, 1685, 1523, 1481, 1326, 821, 790.



3-(4-aminophenyl)-*N***-(quinolin-8-yl)decanamide (3d):** Obtained following general procedure C (65 mg, 83% yield).Red oil. $R_f = 0.51$ (hexane:EtOAc = 1:1). ¹H NMR (CDCl₃, 300 MHz): δ 9.69 (s, 1H), 8.79-8.70 (m, 2H), 8.11 (dd, *J* = 8.3, 1.7 Hz, 1H), 7.51 – 7.38 (m, 3H), 7.14 – 7.03 (m, 2H), 6.84 – 6.41 (m, 2H), 3.66 (br s, 2H), 3.18 (dtd, *J* = 9.5, 7.4, 5.1 Hz, 1H), 2.87 – 2.70 (m, 2H), 1.77 – 1.59 (m, 2H), 1.26 – 1.15 (m, 10H), 0.84 (t, *J* = 6.8 Hz, 3H).¹³C NMR (CDCl₃, 101 MHz): δ 170.8, 148.1, 142.9, 138.4, 136.4, 135.8, 134.6, 128.5,

128-9, 127.5, 121.6, 121.4, 116.6, 116.4, 46.2, 42.0, 36.5, 31.9, 29.7, 29.3, 27.6, 22.7, 14.2. MS m/z 389 (M⁺, 15%), 281 (29), 209 (13), 208 (21), 207 (100), 160 (10). HRMS calcd. for $C_{25}H_{31}N_3O$ (M⁺): 389.2467, found: 389.2463. IR (neat, cm⁻¹) $\tilde{\nu}$: 3351, 2923, 2854, 1731, 1519, 1481, 1322, 825.



N-(quinolin-8-yl)-3-(*p*-tolyl)decanamide (3e): Obtained following general procedure C (73 mg, 97% yield).White solid. m.p. = 40-41 °C. R_f = 0.45 (hexane:EtOAc = 4:1). ¹H NMR (CDCl₃, 400 MHz): δ 9.70 (s, 1H), 8.81 – 8.69 (m, 2H), 8.13 (dd, *J* = 8.3, 1.7 Hz, 1H), 7.56 – 7.39 (m, 3H), 7.32 – 7.28 (m, 4H), 7.21 – 7.11 (m, 1H), 3.36 – 3.21 (m, 1H), 2.85 (dd, *J* = 7.4, 1.6 Hz, 2H), 1.85 –

1.62 (m, 2H), 1.30 – 1.09 (m, 10H), 0.83 (t, J = 6.9 Hz, 3H). ¹³C NMR (CDCl₃, 101 MHz): δ 170.6, 148.0, 144.5, 138.2, 136.6, 134.5, 128.6, 128.0, 127.7, 127.6, 126.5, 121.6, 121.5, 116.7, 46.0, 42.7, 36.4, 31.9, 29.7, 29.3, 27.6, 22.7, 14.2. MS m/z 374 (M⁺, 38%), 341 (11), 289 (43), 282 (14), 281 (37), 276 (17), 275 (18), 253 (21), 209 (13), 208 (21), 207 (100), 191 (11), 187 (12), 186 (89), 172 (12), 171 (54). HRMS calcd. for C₂₅H₃₀N₂O (M⁺): 374.2358, found: 374.2350. IR (neat, cm⁻¹) $\tilde{\nu}$: 3355, 2923, 2854, 1685, 1523, 1481, 1384, 1326, 698.



3-(4-fluorophenyl)-*N***-(quinolin-8-yl)decanamide (3f):** Obtained following general procedure C (74 mg, 94% yield).Brown oil. R_f = 0.42 (hexane:EtOAc = 4:1). ¹H NMR (CDCl₃, 300 MHz): δ 9.70 (s, 1H), 8.80-8.67 (m, 2H), 8.17 (dd, *J* = 8.3, 1.7 Hz, 1H), 7.54 – 7.39 (m, 7H), 3.45 – 3.30 (m, 1H), 2.97 – 2.78 (m, 2H), 1.83 – 1.64 (m, 2H), 1.29 – 1.15 (m, 10H), 0.90 – 0.78 (t, *J* = 6.8 Hz, 3H). ¹⁹F NMR (CDCl₃, 282 MHz): δ -117.0. ¹³C NMR (CDCl₃, 101 MHz): δ 170.3, 161.5 (d, *J* = 243.7 Hz), 147.7, 140.0 (d, *J* = 3.3 Hz), 137.8, 136.8, 134.2, 128.9

(d, *J* = 7.9 Hz), 128.0, 127.5, 121.5, 116.9, 115.3 (d, *J* = 21.1 Hz), 45.9, 42.0, 36.4, 31.8, 29.5, 29.2, 27.4, 22.6, 14.1. MS m/z 292 (M⁺, 45%), 307 (52), 294 (22), 281 (18), 253 (10), 207 (48), 187 (14), 171 (70), 163 (13). HRMS calcd. for $C_{25}H_{29}FN_2O$ (M⁺): 392.2264, found: 392.2258. IR (neat, cm⁻¹) $\tilde{\nu}$: 3351, 2927, 2857, 1685, 1523, 1484, 1326, 1222, 829.



N-(quinolin-8-yl)-3-(4-(trifluoromethyl)phenyl)decanamide (3g): Obtained following general procedure C (84 mg, 95% yield).Brown solid. m.p. = 44-46 ^oC. R_f = 0.40 (hexane:EtOAc = 4:1). ¹H NMR (CDCl₃, 300 MHz): 9.70 (s, 1H), 8.79-8.67 (m, 2H), 8.17 (dd, *J* = 8.3, 1.7 Hz, 1H), 7.54 – 7.39 (m, 7H), 3.45 – 3.30 (m, 1H), 2.97 – 2.78 (m, 2H), 1.83 – 1.64 (m, 2H), 1.29 – 1.15 (m, 10H), 0.90 – 0.78 (t, *J* = 6.8 Hz, 3H). ¹⁹F NMR (CDCl₃, 282 MHz): δ -62.35.¹³C NMR (CDCl₃, 101 MHz): δ 170.1, 148.8, 147.8, 137.2, 134.1, 128.8 (q, *J* = 31.8),

128.2, 128.1, 127.7, 125.6 (q, *J* = 3.6 Hz), 124.4 (q, *J* = 271.8 Hz), 121.8, 121.6, 117.3, 45.5, 42.6, 36.2, 31.9, 29.6, 29.3, 27.5, 22.7, 14.2. MS m/z 442 (M⁺, 35%), 358 (11), 357 (49), 344 (26), 343 (17), 207 (17), 187 (14), 172 (14), 171 (68). HRMS calcd. for $C_{26}H_{29}F_3N_2O_2$ (M⁺): 442.2232, found: 442.2227. IR (neat, cm⁻¹) $\tilde{\nu}$: 3351, 2927, 2858, 1685, 1527, 1481, 1322, 1160, 1118, 829.



Ethyl 4-(1-oxo-1-(quinolin-8-ylamino)decan-3-yl)benzoate (3h): Obtained following general procedure C (87 mg, 97% yield).Yellow oil. $R_f = 0.39$ (hexane:EtOAc = 4:1). ¹H NMR (CDCl₃, 400 MHz): δ 9.70 (s, 1H), 8.76 (dd, J = 4.2, 1.7 Hz, 1H), 8.72 (dd, J = 7.0, 2.0 Hz, 1H), 8.15 (dd, J = 8.3, 1.7 Hz, 1H), 8.02 – 7.95 (m, 2H), 7.56 – 7.42 (m, 3H), 7.42 – 7.35 (m, 2H), 4.35 (q, J = 7.1 Hz, 2H), 3.39 (dtd, J = 9.5, 7.4, 5.3 Hz, 1H), 2.95 – 2.79 (m, 2H), 1.82 (tt, J = 10.3, 5.0 Hz, 1H), 1.73 (tt, J = 9.3, 4.5 Hz, 1H), 1.37 (t, J = 7.1 Hz, 3H), 1.33 –

1.11 (m, 10H), 0.85 (t, J = 6.9 Hz, 3H). ¹³C NMR (CDCl₃, 101 MHz): δ 170.1, 166.7, 149.9, 148.0, 138.1, 136.6, 134.3, 123.0, 128.8, 128.0, 127.7, 127.5, 121.6, 116.8, 60.9, 45.5, 42.8, 36.2, 31.9, 29.6, 29.2, 27.5, 22.7, 14.5, 14.2. MS m/z 446 (M⁺, 7%), 253 (11), 209 (13), 208 (21), 207 (100), 186 (23), 171 (20). HRMS calcd. For C₂₈H₃₄N₂O₃ (M⁺) 446.2569, found: 446.2567. IR (neat, cm⁻¹) $\tilde{\nu}$: 3351, 2927, 2858, 1708, 1608, 1523, 1272, 1106, 787.



3-(4-acetylphenyl)-*N***-(quinolin-8-yl)decanamide (3i):** Obtained following general procedure C (80 mg, 96% yield). Orange oil. $R_f = 0.20$ (hexane:EtOAc = 4:1). ¹H NMR (CDCl₃, 300 MHz): δ 9.72 (s, 1H), 8.74 (dd, *J* = 4.3, 1.7 Hz, 1H), 8.70 (dd, *J* = 6.4, 2.6 Hz, 1H), 8.16 (dd, *J* = 8.3, 1.7 Hz, 1H), 7.93 – 7.85 (m, 2H), 7.54 – 7.34 (m, 5H), 3.38 (p, *J* = 7.5 Hz, 1H), 2.98 – 2.77 (m, 2H), 2.52 (s, 3H), 1.86 – 1.67 (m, 2H), 1.21 (d, *J* = 14.4 Hz, 19H), 0.81 (t, *J* = 6.8 Hz, 3H).¹³C NMR (CDCl₃, 101 MHz): δ 197.9, 170.1, 150.3, 147.6, 137.5, 137.2, 135.5, 133.9,

128.7, 128.0, 127.9, 127.6, 121.7, 121.5, 117.3, 45.2, 42.6, 36.1, 31.8, 29.5, 29.1, 27.4, 26.6, 22.6, 14.1. MS m/z 416 (M⁺, 8%), 331 (15), 281 (27), 253 (13), 209 (13), 208 (20), 207 (100), 186 (30), 171 (26). HRMS calcd. for $C_{27}H_{32}N_2O_2$ (M⁺): 416.2464, found: 416.2455. IR (neat, cm⁻¹) $\tilde{\nu}$: 3351, 2923, 2857, 1681, 1604, 1523, 1481, 1265, 829, 790.



3-(4-nitrophenyl)-*N***-(quinolin-8-yl)decanamide** (**3j)**: Obtained following general procedure C (72 mg, 83% yield). Brown oil. $R_f = 0.54$ (hexane:EtOAc = 4:1). ¹H NMR (CDCl₃, 300 MHz): δ 9.66 (s, 1H), 8.74 (dd, *J* = 4.3, 1.7 Hz, 1H), 8.70 - 8.62 (m, 1H), 8.18 - 8.11 (m, 3H), 7.51 - 7.41 (m, 5H), 3.44 (tt, *J* = 9.0, 5.9 Hz, 1H), 3.01 - 2.77 (m, 2H), 1.86 - 1.61 (m, 2H), 1.32 - 1.11 (m, 10H), 0.84 (t, *J* = 6.8 Hz, 3H). ¹³C NMR (CDCl₃, 101 MHz): δ 169.6, 152.5, 147.9,

146.8, 137.9, 137.0, 134.1, 128.6, 128.1, 127.6, 124.0, 121.9, 121.7, 117.1, 45.2, 42.7, 36.2, 31.9, 29.6, 29.2, 27.5, 22.7, 14.2. MS m/z 419 (M⁺, 3%), 281 (12), 153 (11), 209 (13), 208 (21), 207 (100), 186 (15), 171 (13). HRMS calcd. For $C_{25}H_{29}N_3O_4$ (M⁺): 435.2158, found: 435.2201. IR (neat, cm⁻¹) $\tilde{\nu}$: 3347, 2927, 2858, 1685, 1519, 1484, 1342, 1160.



3-(4-hydroxyphenyl)-*N*-(quinolin-8-yl)decanamide (3k): Obtained following general procedure C (68 mg, 87% yield). Yellow oil. $R_f = 0.21$ (hexane:EtOAc = 4:1). ¹H NMR (CDCl₃, 400 MHz): δ 9.71 (s, 1H), 8.76 (dd, *J* = 4.3, 1.7 Hz, 1H), 8.68 (dd, *J* = 6.2, 2.9 Hz, 1H), 8.11 (dd, *J* = 8.3, 1.7 Hz, 1H), 7.49 – 7.43 (m, 2H), 7.41 (dd, *J* = 8.3, 4.3 Hz, 1H), 7.15 – 7.04 (m, 2H), 6.79 – 6.69 (m, 2H), 5.91 (br. s, 1H), 3.24 – 3.12 (m, 1H), 2.79 (qd, *J* = 14.5, 7.5 Hz, 2H), 1.76 – 1.65 (m, 1H), 1.68 – 1.56 (m, 1H), 1.28 – 1.12 (m, 10H), 0.83 (t, *J* = 6.9 Hz, 3H). ¹³C NMR

 $(\text{CDCl}_3, 101 \text{ MHz}): \delta 171.3, 154.7, 148.1, 138.2, 136.7, 135.8, 134.2, 128.6, 128.1, 127.5, 121.8, 121.7, 117.1, 115.6, 46.2, 42.2, 36.7, 31.9, 29.6, 29.3, 27.5, 22.7, 14.2. MS m/z 390 (M^+, 19%), 305 (11), 253 (11), 207 (100), 186 (14), 171 (20), 161 (11). HRMS calcd. For <math>C_{25}H_{30}N_2O_2$ (M⁺): 390.2307, found: 390.2318. IR (neat, cm⁻¹) $\tilde{\nu}$: 3340. 2923, 2854, 1666, 1523, 1484, 1226, 1160, 825.



3-(4-methoxyphenyl)-*N*-(quinolin-8-yl)octanamide. (4a):^[6] Obtained following general procedure C (74 mg, 98% yield).Brown solid. m.p. = 59-61 °C. $R_f = 0.39$ (hexane:EtOAc = 4:1). ¹H NMR (CDCl₃, 300 MHz): δ 9.69 (s, 1H), 8.85 – 8.64 (m, 2H), 8.15 (dd, *J* = 8.3, 1.7 Hz, 1H), 7.57 – 7.39 (m, 3H), 7.24 – 7.13 (m, 2H), 6.87 – 6.75 (m, 2H), 3.73 (s, 3H), 3.24 (dtd, *J* = 9.4, 7.4, 5.2 Hz, 1H), 2.91 – 2.74 (m, 2H), 1.80 – 1.62 (m, 2H), 1.29 – 1.14 (m, 6H), 0.87 – 0.76

(m, 3H). ¹³C NMR (CDCl₃, 75 MHz): δ 170.8, 158.1, 147.9, 138.0, 136.8, 136.5, 134.4, 128.6, 128.1, 127.6, 121.6, 121.5, 116.9, 114.0, 55.3, 46.2, 42.0, 36.5, 31.9, 27.2, 22.7, 14.2. MS m/z 376 (M⁺, 38%), 341 (17), 327 (11), 319 (12), 282 (11), 281 (36), 253 (25), 209 (14), 208 (22), 207 (100), 191 (12), 186 (15), 175 (22), 171 (26), 161 (11). IR (neat, cm⁻¹) $\tilde{\nu}$: 3355, 2927, 2857, 1685, 1519, 1481, 1245, 825.



3-(4-methoxyphenyl)-*N***-(quinolin-8-yl)butanamide** (**4b**):^[1] Obtained following general procedure C (62 mg, 97% yield).Brown solid. m.p. = 65-66 °C. R_f = 0.34 (hexane:EtOAc = 4:1). ¹H NMR (CDCl₃, 400 MHz): δ 9.84 (s, 1H), 8.84 – 8.75 (m, 2H), 8.30 – 8.17 (m, 1H), 7.58 – 7.45 (m, 3H), 7.32 – 7.24 (m, 2H), 6.89 – 6.81 (m, 2H), 3.76 (s, 3H), 3.47 (h, *J* = 7.1 Hz, 1H), 2.90 (dd, *J* = 14.4, 7.0 Hz, 1H), 2.80 (dd, *J* = 14.4, 7.9 Hz, 1H), 1.40 (d, *J* = 7.0 Hz, 3H). ¹³C NMR (CDCl₃, 101 MHz): δ

170.8, 158.2, 147.5, 138.2, 134.2, 128.2, 127.9, 121.7, 121.6, 114.1, 55.3, 47.2, 36.3, 22.2. MS m/z 320 (M⁺, 21%), 281 (30), 253 (12), 209 (13), 208 (21), 207 (100), 191 (10). IR (neat, cm⁻¹) $\tilde{\nu}$: 3355, 2962, 1685, 1519, 1481, 1245, 825.



2-(4-methoxyphenyl)-*N***-(quinolin-8-yl)cyclohexane-1-carboxamide** (4c):^[1] Obtained following general procedure C (49 mg, 68% yield).Brown solid. m.p. = 68-70 °C. $R_f = 0.61$ (hexane:EtOAc = 4:1). ¹H NMR (CDCl₃, 300 MHz): δ 9.33 (s, 1H), 8.73 – 8.60 (m, 2H), 8.12 (d, *J* = 8.3 Hz, 1H), 7.54 – 7.34 (m, 3H), 7.29 – 7.19 (m, 2H), 6.75 – 6.62 (m, 2H), 3.58 (s, 3H), 3.16 – 3.05 (m, 1H), 3.01 (dt, *J* = 11.9, 4.1 Hz, 1H), 2.47 (qd, *J* = 12.1, 3.6 Hz, 1H), 2.24 (dd, *J* = 13.0, 3.4 Hz, 1H), 2.15 – 1.94 (m, 2H), 1.93 – 1.74 (m, 2H), 1.63 (dd, *J* = 8.7, 4.1 Hz, 1H), 1.53 – 1.43 (m,

1H). ¹³C NMR (CDCl₃, 101 MHz): δ 173.5, 158.0, 147.4, 137.6, 137.2, 136.8, 134.4, 128.8, 128.1, 127.7, 121.3, 121.2, 117.0, 113.8, 55.1, 49.0, 45.1, 29.8, 27.4, 26.3, 22.0. MS m/z 360 (M⁺, 11%), 281 (36), 253 (17), 209 (13), 208 (22), 207 (100). IR (neat, cm⁻¹) $\tilde{\nu}$: 3351, 2923, 2854, 1685, 1520, 1481, 1245, 825.



3-(4-methoxyphenyl)decanoic acid (5a): Obtained in a 0.2 mmol reaction scale (42 mg, 75%). Brown oil. R_f = 0.60 (hexane:EtOAc = 1:1). ¹H NMR (CDCl₃, 300 MHz): δ 7.09 (d, J = 8.6 Hz, 2H), 6.83 (d, J = 8.6 Hz, 2H), 3.79 (s, 3H), 3.01 (dtd, J = 9.0, 7.4, 5.4 Hz, 1H), 2.66 – 2.51 (m, 2H), 1.60 (dddd, J = 21.0, 17.6, 8.2, 5.1 Hz, 2H), 1.27 – 1.13 (m, 10H), 0.85 (t, J = 6.9 Hz, 3H). ¹³C NMR (CDCl₃, 101 MHz): δ 178.6, 158.3, 136.1, 128.4, 114.0, 55.3, 41.9, 41.2, 36.5, 31.9, 29.6, 29.3, 27.4, 22.8, 14.2. MS m/z

278 (M⁺, 38%), 220 (10), 219 (52), 180 (25), 179 (100). HRMS calcd. for $C_{17}H_{26}O_3$ (M⁺): 278.1882, found: 278.1877. IR (neat, cm⁻¹) $\tilde{\nu}$: 2924, 2854, 1704, 1511, 1345, 1037, 825.



N-(quinolin-8-yl)-3-((triisopropylsilyl)ethynyl)decanamide. (6): Obtained in a 0.2 mmol reactio scale (59 mg, 62% yield). Yellow oil. R_f = 0.60 (hexane:EtOAc = 4:1). ¹H NMR (CDCl₃, 300 MHz): δ 9.89 (s, 1H), 8.86 – 8.76 (m, 2H), 8.17 (dd, J = 8.3, 1.7 Hz, 1H), 7.58 – 7.42 (m, 3H), 3.20 – 3.07 (m, 1H), 2.72 (qd, J = 14.1, 7.4 Hz, 2H), 1.70 – 1.46 (m, 4H), 1.33 – 1.22 (m, 8H), 0.94 - 0.75 (m, 24H). ¹³C NMR (CDCl₃, 101 MHz): δ 169.7, 147.7, 137.9, 136.8, 134.3, 128.0, 127.6, 121.6, 121.5, 117.2, 110.5, 82.1, 77.4, 77.0, 76.7, 44.3, 34.9, 31.8, 30.1, 29.2, 27.2, 22.7, 18.5, 14.1, 11.2. MS m/z 449 (M⁺, 1%), 282 (11), 181 (37), 253 (19), 209 (14), 208 (22), 207 (100). HRMS calcd. for C₃₀H₄₆N₂OSi (M⁺): 478.3379, found: 478.3368. IR (neat, cm⁻¹) $\tilde{\nu}$: 3351, 2927, 2858, 1685, 1527, 1481, 1326, 790.



3-ethynyl-N-(quinolin-8-yl)decanamide (7): Prepared according to the published protocol,^[7] compound **6** was charged in round bottom flask, (0.06 mmol, 28 mg) and THF was added (0.1 M). Hydrated TBAF (0.072 mmol, 20.1 mg, 1.2 equiv.) was added. The reaction was allowed to stir at rt. After 2 h, the reaction mixture was concentrated under reduced pressure. Column chromatography of the residue furnished the desired product (16 mg, 86%).

Yellow oil. $R_f = 0.52$ (hexane:EtOAc = 4:1). ¹H NMR (CDCl₃, 500 MHz): δ 9.97 (s, 1H), 8.84 – 8.78 (m, 2H), 8.18 (dd, J = 8.3, 1.7 Hz, 1H), 7.58 – 7.44 (m, 3H), 3.10 – 3.01 (m, 1H), 2.81-2.68 (m, 2H), 2.13 (d, J = 2.4 Hz, 1H), 1.67 – 1.42 (m, 4H), 1.39 – 1.19 (m,8H), 0.91 – 0.84 (m, 3H). ¹³C NMR (CDCl₃, 126 MHz): δ 169.4, 147.9, 138.2, 136.6, 134.4, 128.0, 127.5, 121.6, 121.5, 116.9, 86.4, 70.2, 43.8, 34.6, 31.8, 29.3, 29.2, 28.6, 27.2, 22.6, 14.1. MS m/z 322 (M⁺, 6%), 282 (12), 253 (10), 223 (11), 209 (13), 208 (21), 207 (100). HRMS calcd. for C₂₁H₂₆N₂O (M⁺): 322.2045, found: 322.2044. IR (neat, cm⁻¹) $\tilde{\nu}$: 2927, 2858, 1681, 1527, 1484, 906, 728.



3-(1-benzyl-1*H***-1,2,3-triazol-4-yl)-***N***-(quinolin-8-yl)decanamide (8): Obtained in a 0.2 mmol reaction scale (59 mg, 65% yield). White solid. m.p. = 67-69 °C. R_f = 0.52 (hexane:EtOAc = 1:1). ¹H NMR (CDCl₃, 300 MHz): \delta 9.83 (s, 1H), 8.78 (dd,** *J* **= 4.3, 1.7 Hz, 1H), 8.67 (dd,** *J* **= 5.1, 3.9 Hz, 1H), 8.17 (dd,** *J* **= 8.3, 1.7 Hz, 1H), 7.52 - 7.41 (m, 3H), 7.28 (s, 1H), 7.23 - 7.03 (m, 5H), 5.42 (s, 2H), 3.47 (ddd,** *J* **= 8.5, 6.1, 2.4 Hz, 1H), 3.08 - 2.88 (m, 2H), 1.90 - 1.72 (m, 2H), 1.24 (d,** *J* **= 5.6 Hz, 10H), 0.85 (t,** *J* **= 6.5 Hz, 3H). ¹³C NMR (CDCl₃, 101**

MHz): δ 170.6, 150.6, 148.3, 138.4, 136.4, 135.0, 134.5, 129.0, 128.5, 128.0, 127.8, 127.5, 121.7, 121.6, 121.5, 116.6, 54.0, 43.9, 35.0, 34.0, 31.9, 29.5, 29.3, 27.4, 22.7, 14.2. MS m/z 455 (M⁺, 3%), 312 (11), 311 (53), 283 (10), 269 (22), 185 (27), 170 (18), 144 (12), 143 (39), 90 (100). HRMS calcd. for C₂₈H₃₃N₅O (M⁺): 455.2685, found: 455.2686. IR (neat, cm⁻¹) $\tilde{\nu}$: 2923, 2854, 1708, 1523, 1245, 1172.



3-((4-acetylphenyl)ethynyl)-*N***-(quinolin-8-yl)decanamide (9):** Obtained in a 0.2 mmol reaction scale (40 mg, 45% yield). Yellow oil. $R_f = 0.30$ (hexane:EtOAc = 4:1). ¹H NMR (CDCl₃, 400 MHz): δ 10.03 (s, 1H), 8.82 (dd, *J* = 7.3, 1.7 Hz, 1H), 8.63 (dd, *J* = 4.3, 1.7 Hz, 1H), 8.15 (dd, *J* = 8.3, 1.7 Hz, 1H), 7.86 – 7.69 (m, 2H), 7.55 – 7.50 (m, 2H), 7.43 – 7.37 (m, 3H), 3.28 (ddd, *J* = 13.8, 8.2, 5.8 Hz, 1H), 2.89 – 2.75 (m, 2H), 2.55 (s, 3H), 1.69 – 1.59 (m, 2H), 1.34 – 1.24 (m, 10H), 0.89 – 0.85 (m, 3H). ¹³C NMR (CDCl₃, 101 MHz): δ 197.3, 169.5, 148.0, 138.3, 136.5, 135.8, 134.4, 131.8, 128.7, 128.0, 127.5, 121.6, 121.5, 116.8, 95.7, 82.3, 43.9, 34.8, 31.8, 29.7, 29.3, 29.2, 27.4, 26.5, 22.6,

14.1. MS m/z 440 (M⁺, 2%), 281 (13), 253 (10), 209 (13), 208 (21), 207 (100). HRMS calcd. for $C_{29}H_{32}N_2O_2$ (M⁺): 440.2464, found: 440.2456. IR (neat, cm⁻¹) $\tilde{\nu}$: 3347, 2923, 2854, 1685, 1527, 1261, 1172, 964.

Competitive experiment

Amide **2aa** (59.7 mg, 0.20 mmol), $Pd(OAc)_2$ (4.5 mg, 20 µmol), $NaHCO_3$ (25 mg, 0.30 mmol), 2-pyridone (7.6 mg, 80 µmol), 4-iodoanisole (72 mg, 0.3 mmol) and 1-iodo-4-nitrobenzene (75 mg, 0.3 mmol) were placed in a reaction vial equipped with a stirring bar. The mixture ChCl:acetamide (1:2, 1 mL) was then added, and the mixture was heated at 110 °C for 12 h under air atmosphere. The reaction was then cooled to rt and quenched by addition of water. The crude mixture was extracted with EtOAc (x3),

dried over MgSO₄ and concentrated *in vacuo*. Products were isolated by preparative-TLC affording a mixture of the starting material **2aa**, and the two corresponding arylated products **3a** and **3j**, observing a product ratio of 1.0:1.1 (**3j:3a**).



NMR Spectra



¹³C{¹H} NMR: (101 MHz, CDCl₃) of **2aa**



ла 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -1 f1 (ppm) ¹H NMR: (400 MHz, $CDCI_3$) of **2ab**



¹H NMR: (300 MHz, CDCl₃) of **2b**



¹H NMR: (300 MHz, CDCl₃) of 2c



¹H NMR: (400 MHz, CDCl₃) of **2d**



¹H NMR: (400 MHz, CDCl₃) of **2f**











- 1 150 140 130 120 100 90 f1 (ppm) 170 160





$^{13}\text{C}\{^{1}\text{H}\}$ NMR: (101 MHz, CDCl₃) of 3c



¹H NMR: (300 MHz, CDCl₃) of $\mathbf{3d}$





¹³C{¹H} NMR: (101 MHz, CDCl₃) **3e**



лана и правити и п Правити и п



¹⁹F NMR: (282 MHz, CDCl₃) of **3f**



10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 fl(ppm)

$^{13}\text{C}\{^{1}\text{H}\}$ NMR: (101 MHz, CDCl_3) of 3f



 $^{19}\mathsf{F}$ NMR: (282 MHz, CDCl₃) of **3g**



10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 fl (ppm)

$^{13}\text{C}\{^{1}\text{H}\}$ NMR: (101 MHz, CDCl₃) of 3g



¹H NMR: (400 MHz, CDCl₃) of **3h**



¹H NMR: (300 MHz, CDCl₃) of **3i**



¹H NMR: (300 MHz, $CDCl_3$) of **3**j





 $^{^{13}\}text{C}\{^{1}\text{H}\}$ NMR: (101 MHz, CDCl_3) of 3k

-171.34 -164.73 -164.73 -164.26 -164.26 -164.26 -164.26 -161.6 -161.6 -22.73 -22.73 -14.19







¹H NMR: (300 MHz, $CDCl_3$) of **4c**



$^{13}\text{C}\{^{1}\text{H}\}$ NMR: (101 MHz, CDCl₃) of 4c







^{100 90} f1 (ppm) - 1

¹H NMR: (300 MHz, $CDCI_3$) of **6**





¹H NMR: (300 MHz, $CDCl_3$) of **8**



¹H NMR: (400 MHz, CDCl₃) of **9**



References

- [1] V. G. Zaitsev, D. Shabashov, O. Daugulis, J. Am. Chem. Soc. **2005**, 127, 13154-13155.
- [2] M. Pérez-Gómez, H. Azizollahi, I. Franzoni, E. M. Larin, M. Lautens, J.-A. García-López, *Organometallics* **2019**, *38*, 973-980.
- [3] G. Pelletier, A. B. Charette, *Org. Lett.* **2013**, *15*, 2290-2293.
- [4] H. Yi, H. Chen, C. Bian, Z. Tang, A. K. Singh, X. Qi, X. Yue, Y. Lan, J.-F. Lee, A. Lei, *Chem. Commun.* **2017**, *53*, 6736-6739.
- [5] Z. Wang, J. Ni, Y. Kuninobu, M. Kanai, *Angew. Chem. Int. Ed.* **2014**, *53*, 3496-3499.
- [6] Y. Liu, Y. Zhang, X. Cao, J.-P. Wan, *Beilstein J. Org. Chem.* **2016**, *12*, 1122-1126.
- [7] Y. Ano, M. Tobisu, N. Chatani, J. Am. Chem. Soc. 2011, 133, 12984-12986.